Serum Neurofilament Light Chain and GFAP in Amyotrophic Lateral Sclerosis on a Commercial ECLIA Platform
Muscle & Nerve · 2026
DOI: 10.1002/mus.70397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Nicholas S Streicher. Beteiligte Einrichtung: Department of Neurology, Georgetown University, Washington, DC, USA. Hauptthemen laut MEDLINE: Neurofilament Proteins, Amyotrophic Lateral Sclerosis, Glial Fibrillary Acidic Protein. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction/Aims In amyotrophic lateral sclerosis (ALS), SIMOA‐based studies show that baseline serum neurofilament light chain (NfL) predicts the revised ALS Functional Rating Scale (ALSFRS‐R) decline rate and survival. The Roche Elecsys electrochemiluminescence immunoassay (ECLIA) reports values approximately six‐fold lower; cross‐platform comparison confirms comparable performance, but serial clinical‐practice data remain limited. We assessed whether ECLIA NfL correlates with the ALSFRS‐R decline rate under the sampling conditions of clinical practice, and whether GFAP or S‐100B adds prognostic or disease‐specific information.
Methods
We retrospectively analyzed 58 patients with medical‐record‐confirmed ALS at an academic center (2022–2026). Serum NfL, GFAP, and S‐100B were measured on the Roche Elecsys ECLIA. The NfL‐ALSFRS‐R correlation was assessed within matching windows; serial NfL was examined in patients with repeat draws.
Results
First‐per‐patient NfL median was 7.06 pg/mL (IQR 4.06–17.30). NfL correlated strongly with the ALSFRS‐R decline rate (Spearman r = 0.704, n = 31; r = 0.809 within 90 days, n = 17; both p < 0.0001). Fast progressors had 3.7‐fold higher mean NfL than slow progressors (17.10 vs. 4.64 pg/mL). NfL showed no correlation with King's clinical stage ( r = 0.00). GFAP correlated with age but not with progression rate or disease duration; S‐100B showed no association with progression.
Discussion
Serum NfL on a commercial ECLIA platform retained its strong correlation with progression rate despite unstructured sampling, replicating SIMOA‐based findings at platform‐specific values. NfL tracked the rate of decline rather than the accumulated disease state; GFAP and S‐100B added no prognostic or disease‐specific information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Georgetown University, Washington, DC, USA.
ORCID-Profile: Nicholas S Streicher
Zitieren
APA
Streicher, N. S. (2026). Serum Neurofilament Light Chain and GFAP in Amyotrophic Lateral Sclerosis on a Commercial ECLIA Platform. Muscle & Nerve. https://doi.org/10.1002/mus.70397
Vancouver
Streicher NS. Serum Neurofilament Light Chain and GFAP in Amyotrophic Lateral Sclerosis on a Commercial ECLIA Platform. Muscle & Nerve. 2026. doi:10.1002/mus.70397
BibTeX
@article{Streicher2026,
author = {Streicher, Nicholas S},
title = {Serum Neurofilament Light Chain and GFAP in Amyotrophic Lateral Sclerosis on a Commercial ECLIA Platform},
journal = {Muscle & Nerve},
year = {2026},
doi = {10.1002/mus.70397}
}
EUVIMED